CN Patent

CN115611896A — 含四氢萘啶酮或四氢吡啶并嘧啶酮骨架的化合物及其制备方法与制药用途

Assigned to China Pharmaceutical University · Expires 2023-01-17 · 3y expired

What this patent protects

本发明公开了一类式I所示含四氢萘啶酮或四氢吡啶并嘧啶酮骨架的化合物及其制备方法，本发明通过实验验证，所述含四氢萘啶酮或四氢吡啶并嘧啶酮骨架的化合物对酪蛋白裂解酶P(ClpP)有显著的激动作用，可应用于多种癌症的治疗。

USPTO Abstract

本发明公开了一类式I所示含四氢萘啶酮或四氢吡啶并嘧啶酮骨架的化合物及其制备方法，本发明通过实验验证，所述含四氢萘啶酮或四氢吡啶并嘧啶酮骨架的化合物对酪蛋白裂解酶P(ClpP)有显著的激动作用，可应用于多种癌症的治疗。

Drugs covered by this patent

dordaviprone-hydrochloride (DORDAVIPRONE HYDROCHLORIDE)

Patent Metadata

Patent number: CN115611896A
Jurisdiction: CN
Classification: —
Expires: 2023-01-17
Drug substance claim: No
Drug product claim: No
Assignee: China Pharmaceutical University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.